Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT

Completed · Phase 4

Conditions studied: Healthy

In brief

Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents.

Key facts

Study ID

NCT00478556

Run by

University of Alabama at Birmingham

People needed

300

Starts

2007-08-01

Expected to finish

2009-03-01

Last updated by the study team

2017-04-18

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients at least 19 years of age scheduled for outpatient contrast enhanced abdominal pelvic CT at The Kirklin Clinic in Birmingham Alabama as part of clinical care with the patient's provider will be screened for eligibility.

You may not qualify if…

• Not competent to give consent.
• Pregnant.
• Known allergy to either of the contrast agents.
• Loss of sense of taste or smell.
• Contraindication to oral administration such as aspiration risk.

Where it is running

• The Kirklin Clinic — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.